MTOR and prostate carcinoma: Hyperactivation of the PI3K/Akt/mTOR signaling pathway in prostate cancer is mostly related to mutations in PTEN; however, other abnormalities, such as gain-of-function mutations in PIK3CA or AKT genetic aberrations, have also been detected [127,128].